HOLOGIC, INC. (NASDAQ:HOLX) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On May 10, 2017, Hologic, Inc. issued a press release announcing
its financial results for the second quarter ended April 1, 2017.
A copy of the press release is attached hereto as Exhibit99.1 and
is incorporated herein in its entirety by reference.
Limitation on Incorporation by
Reference.The information furnished in this
Item2.02, including the press release attached hereto as
Exhibit99.1,shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall such information be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act except as set forth by specific reference in such a
filing.
Cautionary Note Regarding Forward-Looking
Statements. Except for historical information
contained in the press release attached as an exhibit hereto, the
press release contains forward-looking statements that involve
certain risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by these
statements. Please refer to the cautionary note in the press
release regarding these forward-looking statements.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit Number | Description | |
| 99.1 |
Press release dated May 10, 2017 of Hologic, Inc. |
About HOLOGIC, INC. (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems. HOLOGIC, INC. (NASDAQ:HOLX) Recent Trading Information
HOLOGIC, INC. (NASDAQ:HOLX) closed its last trading session up +0.39 at 45.96 with 2,454,731 shares trading hands.
